Uroplasty — Investor Presentation (November 2007)
26 slides from Uroplasty's investor presentation, Nov 7, 2007
Slide 1: Common Stock Offering Investor Presentation
Common Stock Offering Investor Presentation November 2007 Presented by David Kaysen, President & CEO Medi Jiwani, Vice President, CFO & Treasurer
Slide 2: Forward Looking Statement
This presentation includes forward-looking statements, including financial projections, relating to our business plan and growth strategies. For many reasons we may not achieve our financial objectives or successfully grow our business. Our reports filed with the U.S. Securities and Exchange Commiss
Slide 3: Introduction
Issuer: Uroplasty, Inc. Offering Size: 3,000,000 shares of common stock - 100% primary Use of Proceeds: Expand U.S. sales and marketing organization, conduct clinical trials, general working capital purposes AMEX Listing: American Stock Exchange "UPI" Closing Price(1): $4.20 Market Capitalization(1)
Slide 4: Who we are
Who we are We are a medical device company that provides unique products for the treatment of urinary voiding dysfunctions. Our primary focus is the commercialization of our Urgent(r) PC system, which we believe is the only non-surgical neurostimulation therapy for the treatment of overactive bladde
Slide 5: Investment highlights
Experienced management team with strong track record of execution and demonstrated medical device success Large and growing market opportunity The U.S. neurostimulation device market is expected to grow from approximately $628 million in 2006 to approximately $2 billion in 2012 Overactive bladder (O
Slide 6: Urgent PC is the Growth Driver
Urgent PC is the Growth Driver (+36%) (+50-57%) (+30-40%) $6.0 $6.5- $7.0
Slide 7: Legacy Product - Macroplastique
Legacy Product - Macroplastique Biocompatible urethral bulking agent Unique delivery system ensures precise implantation 30-min office based/outpatient procedure Minimally invasive treatment Macroplastique is an injectable soft-tissue bulking agent used to treat adult female stress urinary incontine
Slide 8: $3.1 Billion U.S. Market
$3.1 Billion U.S. Market Our primary demographic is women between 40 and 60 years old 3 Million patients Stress Urge Incontinence 34 Million patients Urgency Frequency Urge Incontinence 9 Million patients Involuntary leaking during increased intra-abdominal pressure
Slide 9: Treatment Options - OAB Continuum of Care
Treatment Options - OAB Continuum of Care Treatment Company and Product Names Position Drug Therapy Pharmacia - Detrol(r) ALZA - Ditropan(r) Watson Pharma - Oxytrol(r) Negative side effects Surgery Medtronic - InterStim(r) Expensive procedure and invasive surgery Neuro Stimulation Uroplasty - Urgent
Slide 10: Urgent PC - Neurostimulation
Urgent PC - Neurostimulation Consists of handheld stimulator with lead set 30-minute office based treatment, can be nurse administered Minimally invasive The Urgent PC Neurostimulation System provides percutaneous tibial nerve stimulation (PTNS) for the treatment of urinary urgency, urinary frequenc
Slide 11: Urgent PC U.S. Sales Strategy
Urgent PC U.S. Sales Strategy Direct U.S. Sales force is currently comprised of 17 direct representatives supplemented by 11 independent representatives Target Market: ^8,500 Total U.S. Urologists/Urogynecologists Market Penetration Today Target Market Penetration 3 Years From Today ^2% ^20%
Slide 12: U.S. Market Coverage
U.S. Market Coverage Hawaii Employed Sales Representative (17) Independent Sales Representative (11) Employed Representative to be added (3)
Slide 13: Urgent PC Marketing Strategy
Urgent PC Marketing Strategy We intend to market the Urgent PC brand with the following strategies... Clinical trials to educate the doctor community Patient education and literature for doctors offices Physician & Nursing Society Meetings Investor Relations Website Redesign Patient referral UPC foc
Slide 14: Physician Economics with Urgent PC
Physician Economics with Urgent PC Economics are very compelling for physicians...
Slide 15: International Market Coverage
International Market Coverage United Kingdom Employed Sales Representative (5) Independent Sales Representative (1) International - Distributors Presence in 43 countries worldwide throughout: Europe North America South America Central America Africa Middle East Asia Australia
Slide 16: Management Team
Name Title Previous Experience Dave Kaysen President & CEO Diametrics, Rehabilicare Medi Jiwani CFO Gedney, Telex Communications, Tennant Susan Holman COO Bioplasty, Bio-Vascular Larry Heinemann VP Sales C.R. Bard Nancy Kolb VP Marketing Inlet Medical, Gyrus Medical Marc Herregraven VP Manufacturing
Slide 17: Financial Presentation
FINANCIAL PRESENTATION
Slide 18: Revenue Growth
Revenue Growth $6.0 $6.5 - $7.0 (+36%) (+50-57%) (+30-40%) Projected operating profit (excluding non-cash charges) breakeven at $14 to $16 million sales
Slide 19: Urgent PC is the Growth Driver
Urgent PC is the Growth Driver
Slide 20: Financial Model (non-GAAP)
Financial Model (non-GAAP) Adjusted Gross Profit 7% om ah 79%) | 75-80% Adjusted Operating Expenses: General & Adrrinistration 45% 2 29% 24% | 8.10% Research & Development 5% 2% 1% 13%] | 10-16% Sales & Marketing 55h ot 5Fh 62%) | 25.30% Total Adjusted Operating Expenses 168% 117% oF 90%) [43-52% Ad
Slide 21: Income Statement (non-GAAP)
Income Statement (non-GAAP)
Slide 22: Balance Sheet / Cap Structure
Balance Sheet / Cap Structure Notes: (1) Results as of September 30, 2007 unaudited (2) Current cash balance & credit facilities expected to provide sufficient liquidity through June 30, 2008 (3) Assumes a $12.4 million offering less fees and expenses Potential to raise $1.9 million from early call
Slide 23: Investment highlights
Experienced management team with strong track record of execution and demonstrated medical device success Large and growing market opportunity The U.S. neurostimulation device market is expected to grow from approximately $628 million in 2006 to approximately $2 billion in 2012 Overactive bladder (O
Slide 24: Reconciliation of non-GAAP to GAAP financial measures
Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures
Slide 25: Reconciliation of non-GAAP to GAAP financial measures
Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures
Slide 26: Reconciliation of non-GAAP to GAAP financial measures
Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures